Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic-guidance systems and complementary products are used to conduct spine and brain procedures in an accurate and secure manner. It also offers Mazor X, a renaissance system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MZOR
CUSIPN/A
Phone972-4618-7101
Debt
Debt-to-Equity RatioN/A
Current Ratio7.34
Quick Ratio6.92
Price-To-Earnings
Trailing P/E Ratio-115.76
Forward P/E Ratio-483.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$64.95 million
Price / Sales23.51
Cash FlowN/A
Price / CashN/A
Book Value$4.46 per share
Price / Book13.00
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-12,410,000.00
Net Margins-12.80%
Return on Equity-7.17%
Return on Assets-6.26%
Miscellaneous
Employees194
Outstanding Shares26,330,000
Market Cap$1.54 billion
Mazor Robotics (NASDAQ:MZOR) Frequently Asked Questions
What is Mazor Robotics' stock symbol?
Mazor Robotics trades on the NASDAQ under the ticker symbol "MZOR."
How were Mazor Robotics' earnings last quarter?
Mazor Robotics Ltd - (NASDAQ:MZOR) released its earnings results on Thursday, August, 2nd. The medical instruments supplier reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.13. The medical instruments supplier earned $13.20 million during the quarter, compared to analyst estimates of $17.02 million. Mazor Robotics had a negative net margin of 12.80% and a negative return on equity of 7.17%. The business's revenue for the quarter was down 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.05) earnings per share. View Mazor Robotics' Earnings History.
When is Mazor Robotics' next earnings date?
What price target have analysts set for MZOR?
5 Wall Street analysts have issued 1-year price objectives for Mazor Robotics' shares. Their predictions range from $36.00 to $67.00. On average, they anticipate Mazor Robotics' stock price to reach $55.50 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for Mazor Robotics.
What is the consensus analysts' recommendation for Mazor Robotics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mazor Robotics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mazor Robotics.
What are Wall Street analysts saying about Mazor Robotics stock?
Here are some recent quotes from research analysts about Mazor Robotics stock:
- 1. According to Zacks Investment Research, "Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. " (9/28/2018)
- 2. Needham & Company LLC analysts commented, "MZOR missed consensus revenue and EPS as its sales declined by 14% due to lower pricing under the MDT agreement. We estimate that MZOR sold 20 systems in 2Q18, which is up sequentially from 17 in 1Q18 and above our estimate of 17. MZOR’s recurring revenue of $6.3M missed our $9.2M estimate. MZOR and MDT plan to introduce a new system that combines the Mazor X robotic and StealthStation navigation systems at NASS and we think it should help to make Mazor X more competitive with GMED’s ExcelsiusGPS. But we don’t expect this to have a material impact on sales until 2019 and in the meantime we believe that the Mazor X remains at a disadvantage. Despite today’s decline, MZOR shares are still trading at an EV/sales multiple of 17.8x our 2018E estimate vs. its small/mid-cap growth peers at 11.1x. We maintain our Underperform rating." (8/2/2018)
Are investors shorting Mazor Robotics?
Mazor Robotics saw a decrease in short interest during the month of September. As of September 28th, there was short interest totalling 1,807,041 shares, a decrease of 41.3% from the September 14th total of 3,079,746 shares. Based on an average trading volume of 1,538,428 shares, the short-interest ratio is presently 1.2 days. View Mazor Robotics' Current Options Chain.
Who are some of Mazor Robotics' key competitors?
Some companies that are related to Mazor Robotics include Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Penumbra (PEN), Novocure (NVCR), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Glaukos (GKOS), Nevro (NVRO), Luminex (LMNX) and Cardiovascular Systems (CSII).
Who are Mazor Robotics' key executives?
Mazor Robotics' management team includes the folowing people:
- Mr. Ori Hadomi, CEO & Director (Age 51)
- Mr. Eliyahu Zehavi, Co-Founder & Exec. VP of Advanced Technologies (Age 63)
- Ms. Sharon Levita, CFO, VP of Bus. Operations & Company Sec. (Age 51)
- Mr. Christopher Prentice, Chief Commercial Officer (Age 48)
- Prof. Moshe Shoham, Co-Founder & CTO (Age 66)
Who are Mazor Robotics' major shareholders?
Mazor Robotics' stock is owned by many different of retail and institutional investors. Top institutional investors include Dorsey Wright & Associates (0.37%), Kassirer Asset Management Corp (0.08%), NEXT Financial Group Inc (0.01%) and American National Bank (0.01%).
Which major investors are selling Mazor Robotics stock?
MZOR stock was sold by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates and American National Bank.
Which major investors are buying Mazor Robotics stock?
MZOR stock was bought by a variety of institutional investors in the last quarter, including Kassirer Asset Management Corp and NEXT Financial Group Inc.
How do I buy shares of Mazor Robotics?
Shares of MZOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mazor Robotics' stock price today?
One share of MZOR stock can currently be purchased for approximately $58.00.
How big of a company is Mazor Robotics?
Mazor Robotics has a market capitalization of $1.54 billion and generates $64.95 million in revenue each year. The medical instruments supplier earns $-12,410,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Mazor Robotics employs 194 workers across the globe.
What is Mazor Robotics' official website?
How can I contact Mazor Robotics?
Mazor Robotics' mailing address is 5 SHACHAM STREET NORTH INDUSTRIAL PARK, CAESAREA L3, 3088900. The medical instruments supplier can be reached via phone at 972-4618-7101 or via email at [email protected]
MarketBeat Community Rating for Mazor Robotics (NASDAQ MZOR)
MarketBeat's community ratings are surveys of what our community members think about Mazor Robotics and other stocks. Vote "Outperform" if you believe MZOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MZOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
